Market cap
₹453 Cr
Recently Viewed
Clear AllNSE: ZIMLAB | BSE: 541400
₹86.06
₹-0.07
(-0.08%)
As on 28-Apr-2026IST
Market cap
₹453 Cr
Revenue (TTM)
₹378 Cr
P/E Ratio
64.9
P/B Ratio
1.6
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹7 Cr
ROE
5 %
ROCE
8.3 %
Industry P/E
29.53
EV/EBITDA
12.8
Debt to Equity
0.4
Book Value
₹54.3
EPS
₹1.4
Face value
10
Shares outstanding
53,549,037
CFO
₹324.20 Cr
EBITDA
₹377.90 Cr
Net Profit
₹137.15 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zim Laboratories
| 19.3 | 35.6 | 22.7 | -2.3 | 2.7 | -- | -- |
|
BSE Healthcare
| 2.6 | 5.0 | 8.0 | 6.4 | 25.0 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Zim Laboratories
| -33.5 | -9.0 | 18.7 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zim Laboratories
|
86.1 | 453.5 | 377.9 | 7.0 | 4.6 | 2.8 | 64.9 | 1.6 |
| 2,756.0 | 34,418.5 | 5,201.6 | 1,014.6 | 22.9 | 25 | 33.9 | 7.5 | |
| 8,465.5 | 21,144.6 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.3 | 25.4 | |
| 1,732.2 | 13,164.9 | 2,089.5 | 622.0 | 31.3 | 20.4 | 21.5 | 4.0 | |
| 1,327.6 | 18,343.8 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.5 | 5.1 | |
| 2,043.6 | 32,811.8 | 4,193.0 | 753.8 | 22.7 | 20.8 | 43.5 | 8.2 | |
| 4,820.1 | 22,031.4 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.8 | 5.5 | |
| 5,112.9 | 8,480.8 | 1,348.5 | 293.5 | 28.1 | 50.7 | 28.9 | 12.2 | |
| 407.8 | 7,980.7 | 1,432.0 | 149.0 | 19.1 | 7.9 | 53.2 | 3.2 | |
| 1,052.0 | 9,701.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 19 | 3.3 |
No Review & Analysis are available.
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished... formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India. Read more
Incorporated
1984
Chairman
Anwar Siraj Daud
Managing Director
Anwar Siraj Daud
Group
MNC
Headquarters
Nagpur, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Zim Laboratories Ltd is ₹86.06 (NSE) and ₹84.68 (BSE) as of 28-Apr-2026 IST. Zim Laboratories Ltd has given a return of 2.66% in the last 3 years.
The P/E ratio of Zim Laboratories Ltd is 64.94 times as on 28-Apr-2026, a 120 premium to its peers’ median range of 29.53 times.
The P/B ratio of Zim Laboratories Ltd is 1.56 times as on 28-Apr-2026, a 66 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
32.12
|
1.56
|
|
2024
|
26.98
|
1.95
|
|
2023
|
14.44
|
1.76
|
|
2022
|
5.95
|
1.48
|
|
2021
|
5.36
|
0.73
|
The 52-week high and low of Zim Laboratories Ltd are Rs 127.00 and Rs 59.31 as of 28-Apr-2026.
Zim Laboratories Ltd has a market capitalisation of ₹ 453 Cr as on 28-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Zim Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.